Search results
Results From The WOW.Com Content Network
The vaccine delivery method/route may vary. They may be given by injection, dermal application, or nasal/ocular application. Injection routes may be intra-muscular (IM) or subcutaneous (SQ). The specific injection site may vary depending on the type of vaccine (MLV vs killed) being given.
A vaccine-associated sarcoma (VAS) or feline injection-site sarcoma (FISS) is a type of malignant tumor found in cats (and, often, dogs and ferrets) which has been linked to certain vaccines. VAS has become a concern for veterinarians and cat owners alike and has resulted in changes in recommended vaccine protocols.
Subcutaneous injection sites. Commonly used injection sites include: [3]: 723 The outer area of the upper arm. The abdomen, avoiding a 2-inch circle around the navel. The front of the thigh, between 4 inches from the top of the thigh and 4 inches above the knee. The upper back. The upper area of the buttock, just behind the hip bone.
Cefovecin is a broad-spectrum, third-generation cephalosporin antibiotic administered by subcutaneous injection. [4] It is used to treat skin and soft tissue infections in dogs and cats. [4] The antimicrobial effects last for 14 days following administration. [5]
Intramuscular injection is the administration of a drug deep into the muscles via a needle, which allows the drug to go into the bloodstream as well. Subcutaneous injections occur when the needle is inserted between the skin and muscle, allowing the drug to be absorbed into the bloodstream over a prolonged period. [27]
One of the most common side effects of subcutaneous administration is moderate to severe pain at the injection site. [10] Although the manufacturer recommends keeping maropitant at room temperature, many people have noted that keeping it in the fridge reduces the sting upon injection.
Injection site reactions (ISRs) are reactions that occur at the site of injection of a drug. They may be mild or severe and may or may not require medical intervention. Some reactions may appear immediately after injection, and some may be delayed. [1] Such reactions can occur with subcutaneous, intramuscular, or intravenous administration.
Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3] The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, [3] and it was approved by the European Medicines Agency in 2017. [4]